T-cell receptor therapy shows promise in multiple myeloma.
Bagcchi S. Lancet Oncol. 2015 Jul 23. pii: S1470-2045(15)00191-6. doi: 10.1016/S1470-2045(15)00191-6. [Epub ahead of print].
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Rapoport AP et al. Nat Med. 2015 Jul 20. doi: 10.1038/nm.3910. [Epub ahead of print].
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N et al. JAMA Oncol. 2015 Jul 2. doi: 10.1001/jamaoncol.2015.2010. [Epub ahead of print].
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
Bendell JC et al. Cancer. 2015 Jul 15. doi: 10.1002/cncr.29422. [Epub ahead of print].
Ixazomib for the treatment of multiple myeloma.
Gentile M et al. Expert Opin Investig Drugs. 2015 Jul 3:1-12. [Epub ahead of print].
Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart AK et al. Future Oncol. 2015 Jun 30:1-16. [Epub ahead of print].